Literature DB >> 10214487

Cell-extracellular matrix interaction in glioma invasion.

R H Goldbrunner1, J J Bernstein, J C Tonn.   

Abstract

Astrocytic tumours of the central nervous system express cell adhesion receptors of the integrin superfamily, CD44 and adhesion receptors of the immunoglobulin superfamily. Glioma cells utilize these receptors to adhere to and migrate along components of the extracellular matrix (ECM), which is uniquely distributed and regulated within the brain and the spinal cord. For penetration into healthy brain tissue a number of proteases are expressed, which degrade proteins of the extracellular matrix. Thus, glioma cell invasion into the adjacent brain tissue is dependent on the interaction of glioma cells with the extracellular matrix and the subsequent destruction of matrix barriers. There is a critical balance between expression of various adhesion receptors and proteases. The tight regulation of critical levels of proteases and receptors expressed by glioma cells or other cells is necessary for the "physiological" behaviour of glioma cells. Shifts in the balance of protein expression determine glioma cell behaviour in their micro-environment and can initiate or influence the complex process of glioma cell invasion. The complex receptor-ECM interaction in glioma cell invasion is discussed focussing upon the role of integrin receptors and matrix-metalloproteinases. Influencing these molecules or their regulation may lead to novel therapeutic approaches in the treatment of malignant glioma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214487     DOI: 10.1007/s007010050301

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  40 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Human and rat glioma growth, invasion, and vascularization in a novel chick embryo brain tumor model.

Authors:  Alexandra Cretu; Joseph S Fotos; Brian W Little; Deni S Galileo
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

Review 4.  Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion.

Authors:  H L Fillmore; T E VanMeter; W C Broaddus
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

5.  Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels.

Authors:  Shreyas S Rao; Jessica Dejesus; Aaron R Short; Jose J Otero; Atom Sarkar; Jessica O Winter
Journal:  ACS Appl Mater Interfaces       Date:  2013-09-06       Impact factor: 9.229

Review 6.  Models for assessment of angiogenesis in gliomas.

Authors:  R H Goldbrunner; S Wagner; K Roosen; J C Tonn
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 7.  Vascular microenvironment in gliomas.

Authors:  P Vajkoczy; M D Menger
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 8.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 9.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

10.  Poliovirus receptor CD155-targeted oncolysis of glioma.

Authors:  Melinda K Merrill; Guenter Bernhardt; John H Sampson; Carol J Wikstrand; Darell D Bigner; Matthias Gromeier
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.